Fidaxomicin (Dificlir®) may be considered a cost-effective use of resources. It should be prescribed according to the recommendations outlined in the recently updated National Clostridium difficile Guidelines (due to be completed in February 2013 www.hpsc.ie).
The NCPE recommendation on ivacaftor (Kalydeco®), led to follow-up discussions between the HSE CPU and the company, Vertex Pharmaceuticals, resulting in a positive recommendation on the provision of the drug for Irish CF patients, whilst at the same time significantly reducing the budget impact of the drug.
The NCPE recommends reimbursement of bendamustine (Levact®) for patients unable to tolerate fludarabine/clyclophosphamide.
The NCPE believe that, at the submitted price, eribulin (Halaven®) is not cost effective for the treatment of patients with locally advanced breast cancer or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease.
For the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. The NCPE believe that, at the submitted price, vemurafenib (Zelboraf®) is not cost effective for this indication.
As the manufacturer is unable to demonstrate the cost-effectiveness of fampridine we are unable to recommend reimbursement
The NCPE believe that apixaban is cost effective for this indication
Following a price revision we now consider rivaroxaban a cost-effective therapy for this indication.
The NCPE believe that, at the submitted price, Abiraterone Acetate (Zytiga®) is not cost-effective for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)
We believe that at the submitted price, Ozurdex® cannot be considered cost-effective therapy for the treatment of macular oedema following retinal vein occlusion.